Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Sustiva through Computation of Resistance Profiles
- 1 December 2000
- journal article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 122 (51) , 12898-12900
- https://doi.org/10.1021/ja003113r
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Selective Interaction of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Nonnucleoside Inhibitor Efavirenz and Its Thio-Substituted Analog with Different Enzyme-Substrate ComplexesAntimicrobial Agents and Chemotherapy, 2000
- Design of MKC-442 (Emivirine) Analogues with Improved Activity Against Drug-Resistant HIV MutantsJournal of Medicinal Chemistry, 1999
- The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.1Antiviral Research, 1998
- Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside InhibitorsJournal of Medicinal Chemistry, 1996
- Locations of Anti-AIDS Drug Binding Sites and Resistance Mutations in the Three-dimensional Structure of HIV-1 Reverse TranscriptaseJournal of Molecular Biology, 1994
- Fidelity of HIV-1 Reverse TranscriptaseScience, 1988